Apotex Takes Cozaar, Hyzaar Exclusivity Dispute to Supreme Court

Apotex has asked the Supreme Court to hear a case that could have a lasting impact on how initial marketing exclusivity is awarded to generic-drug manufacturers. Apotex’s petition for a writ of certiorari involves a dispute over the FDA’s awarding, earlier this year, of 180 days of marketing exclusivity to Teva as the first company to challenge a patent on Merck’s hypertension drugs Cozaar (losartan potassium) and Hyzaar (hydrochlorothiazide/losartan potassium).
Washington Drug Letter